loading page

Association of hypernatremia with mortality in patients with COVID-19: a systematic review and meta-analysis
  • Yongzhi Ma,
  • 盼娟 张,
  • Ming Hou
Yongzhi Ma
Qinghai University Affiliated Hospital
Author Profile
盼娟 张
Qinghai University Affiliated Hospital
Author Profile
Ming Hou
Qinghai University Affiliated Hospital

Corresponding Author:[email protected]

Author Profile

Abstract

Abstract Background: The purpose of this meta-analysis was to look at the relationship between hypernatremia and mortality in COVID-19 patients. Methods: We searched the PubMed, Web of science, Embase and Cochrane databases for articles published from the inception of the database until August 27, 2022. Three researchers reviewed the literature, retrieved data, and assessed the quality of the literature, respectively. A meta-analysis was performed using State 17 software to assess the value of the effect of hypernatremia on mortality in patients with new coronavirus pneumonia. Results: A total of 9 publications was finally included in this study, including a total of 11,801 patients with COVID-19, including 1,278 in the hypernatremia group and 10,523 in the normonatremia group. Meta-analysis showed that hypernatremia was associated with mortality in patients with COVID-19 [OR = 4.15, 95% CI (2.95-5.84), P = 0.002, I² = 66.7%] with a sensitivity of 0.36 [0.26, 0.48] and a specificity of 0.88 [ 0.83, 0.91]. The posterior probability of mortality was 42% in patients with COVID-19 hypernatremia and 15% in patients who did not have COVID-19 hypernatremia. Conclusion: According to available data, hypernatremia is associated with death in patients with COVID-19.
29 Aug 2023Submitted to Immunity, Inflammation and Disease
04 Sep 2023Submission Checks Completed
04 Sep 2023Assigned to Editor
04 Sep 2023Review(s) Completed, Editorial Evaluation Pending
06 Sep 2023Reviewer(s) Assigned
31 Oct 2023Editorial Decision: Revise Minor
06 Nov 20231st Revision Received
07 Nov 2023Assigned to Editor
07 Nov 2023Submission Checks Completed
07 Nov 2023Review(s) Completed, Editorial Evaluation Pending
09 Nov 2023Reviewer(s) Assigned
09 Nov 2023Editorial Decision: Revise Minor
13 Nov 20232nd Revision Received
19 Nov 2023Assigned to Editor
19 Nov 2023Submission Checks Completed
19 Nov 2023Review(s) Completed, Editorial Evaluation Pending
19 Nov 2023Reviewer(s) Assigned
20 Nov 2023Editorial Decision: Accept
Dec 2023Published in Immunity, Inflammation and Disease volume 11 issue 12. https://doi.org/10.1002/iid3.1109